Results 361 to 370 of about 297,887 (387)
Some of the next articles are maybe not open access.
Diabetes Research and Clinical Practice, 2018
Metformin is a lipophilic biguanide which inhibits hepatic gluconeogenesis and improves peripheral utilization of glucose. It is the first line pharmacotherapy for glucose control in patients with Type 2 diabetes due to its safety, efficacy and tolerability.
Tahseen A Chowdhury, Ritwika Mallik
openaire +3 more sources
Metformin is a lipophilic biguanide which inhibits hepatic gluconeogenesis and improves peripheral utilization of glucose. It is the first line pharmacotherapy for glucose control in patients with Type 2 diabetes due to its safety, efficacy and tolerability.
Tahseen A Chowdhury, Ritwika Mallik
openaire +3 more sources
Regulatory Toxicology and Pharmacology, 2018
This review investigates the different biological effect of Metformin (MET) in different conditions. MET is an oral antidiabetic drug used for the treatment of type 2 diabetes mellitus (T2DM) particularly in overweight people. The main mechanism of action of the MET is inhibition of hepatic glucose production and reduction of insulin resistance.
Tuğba Adak +3 more
openaire +3 more sources
This review investigates the different biological effect of Metformin (MET) in different conditions. MET is an oral antidiabetic drug used for the treatment of type 2 diabetes mellitus (T2DM) particularly in overweight people. The main mechanism of action of the MET is inhibition of hepatic glucose production and reduction of insulin resistance.
Tuğba Adak +3 more
openaire +3 more sources
General Pharmacology: The Vascular System, 1993
Metformin (dimethylbiguanide) is an antihyperglycaemic drug used to treat non-insulin dependent diabetes mellitus. It acts in the presence of insulin to increase glucose utilization and reduce glucose production, thereby countering insulin resistance.
openaire +3 more sources
Metformin (dimethylbiguanide) is an antihyperglycaemic drug used to treat non-insulin dependent diabetes mellitus. It acts in the presence of insulin to increase glucose utilization and reduce glucose production, thereby countering insulin resistance.
openaire +3 more sources
Rejuvenation Research, 2011
Abstract Geroprotectors are drugs that decrease the rate of aging and therefore extend life span. Metformin has been described as a geroprotector, and several studies have shown that metformin can slow down the rate of aging. The mechanisms behind the geroprotective effect of metformin are less established.
openaire +3 more sources
Abstract Geroprotectors are drugs that decrease the rate of aging and therefore extend life span. Metformin has been described as a geroprotector, and several studies have shown that metformin can slow down the rate of aging. The mechanisms behind the geroprotective effect of metformin are less established.
openaire +3 more sources
Scandinavian Journal of Haematology, 1969
A clinical series of 40 patients was observed for 5 months, in the course of which every patient took 1.5 g. metformin daily for 3 months. No increase in fibrinolytic activity was demonstrable by euglobulin lysis test during the course of treatment. Nor did the fibrinogen and cholesterol values change. Blood glucose decreased.
openaire +3 more sources
A clinical series of 40 patients was observed for 5 months, in the course of which every patient took 1.5 g. metformin daily for 3 months. No increase in fibrinolytic activity was demonstrable by euglobulin lysis test during the course of treatment. Nor did the fibrinogen and cholesterol values change. Blood glucose decreased.
openaire +3 more sources
Drugs, 2005
The thiazolidinedione rosiglitazone and the biguanide metformin are effective antihyperglycaemic agents with different modes of action; rosiglitazone primarily increases insulin sensitivity, whereas metformin primarily reduces hepatic glucose output. Antihyperglycaemic combination therapy is often required to achieve effective glycaemic control.
openaire +3 more sources
The thiazolidinedione rosiglitazone and the biguanide metformin are effective antihyperglycaemic agents with different modes of action; rosiglitazone primarily increases insulin sensitivity, whereas metformin primarily reduces hepatic glucose output. Antihyperglycaemic combination therapy is often required to achieve effective glycaemic control.
openaire +3 more sources
Diabetes & Metabolism, 2014
These case reports demonstrate that, at the individual level, blood metformin concentrations and metformin effects on lactate do not always correlate.We report here on two unusual cases: metformin accumulation in the absence of hyperlactataemia; and metformin-induced hyperlactataemia with no metformin accumulation.Patient #1 presented with severe ...
Rachel Desailloud +4 more
openaire +3 more sources
These case reports demonstrate that, at the individual level, blood metformin concentrations and metformin effects on lactate do not always correlate.We report here on two unusual cases: metformin accumulation in the absence of hyperlactataemia; and metformin-induced hyperlactataemia with no metformin accumulation.Patient #1 presented with severe ...
Rachel Desailloud +4 more
openaire +3 more sources
2016
Metformin is the most widely prescribed antidiabetic drug in the world. Despite its beneficial effects in reducing the risk for developing vascular complications associated with diabetes, the glycemic response to metformin is highly variable. Genetic factors, along with factors such as various comorbidities and body weight, contribute to this ...
Yee, Sook Wah +2 more
openaire +3 more sources
Metformin is the most widely prescribed antidiabetic drug in the world. Despite its beneficial effects in reducing the risk for developing vascular complications associated with diabetes, the glycemic response to metformin is highly variable. Genetic factors, along with factors such as various comorbidities and body weight, contribute to this ...
Yee, Sook Wah +2 more
openaire +3 more sources